- Home
- MYPS vs SAVA Comparison
MYPS vs SAVA Comparison
Compare MYPS & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYPS
- SAVA
- Stock Information
- Founded
- MYPS 2011
- SAVA 1998
- Country
- MYPS United States
- SAVA United States
- Employees
- MYPS N/A
- SAVA N/A
- Industry
- MYPS EDP Services
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- MYPS Technology
- SAVA Health Care
- Exchange
- MYPS Nasdaq
- SAVA Nasdaq
- Market Cap
- MYPS 121.6M
- SAVA 102.4M
- IPO Year
- MYPS N/A
- SAVA N/A
- Fundamental
- Price
- MYPS $0.97
- SAVA $2.11
- Analyst Decision
- MYPS Buy
- SAVA Hold
- Analyst Count
- MYPS 5
- SAVA 1
- Target Price
- MYPS $2.50
- SAVA $2.00
- AVG Volume (30 Days)
- MYPS 229.4K
- SAVA 518.9K
- Earning Date
- MYPS 11-03-2025
- SAVA 11-06-2025
- Dividend Yield
- MYPS N/A
- SAVA N/A
- EPS Growth
- MYPS N/A
- SAVA N/A
- EPS
- MYPS N/A
- SAVA N/A
- Revenue
- MYPS $261,058,000.00
- SAVA N/A
- Revenue This Year
- MYPS N/A
- SAVA N/A
- Revenue Next Year
- MYPS N/A
- SAVA N/A
- P/E Ratio
- MYPS N/A
- SAVA N/A
- Revenue Growth
- MYPS N/A
- SAVA N/A
- 52 Week Low
- MYPS $0.90
- SAVA $1.15
- 52 Week High
- MYPS $2.29
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- MYPS 40.45
- SAVA 44.15
- Support Level
- MYPS $0.94
- SAVA $2.12
- Resistance Level
- MYPS $0.98
- SAVA $2.19
- Average True Range (ATR)
- MYPS 0.03
- SAVA 0.10
- MACD
- MYPS 0.01
- SAVA -0.02
- Stochastic Oscillator
- MYPS 21.49
- SAVA 6.45
About MYPS PLAYSTUDIOS Inc.
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Company's games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.